Literature DB >> 29974206

Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis : Six new cases and a literature review.

Ulf Kallweit1,2, Claudio L A Bassetti3, Michael Oberholzer1, Rolf Fronczek4, Mathieu Béguin1, Matthias Strub5, Gert Jan Lammers4,6.   

Abstract

BACKGROUND: There are increasing data suggesting the involvement of the immune system in narcolepsy. The co-occurrence of narcolepsy with other autoimmune disorders (including multiple sclerosis, MS) is rare. PATIENTS AND METHODS: International multicenter sleep center survey and literature review on narcolepsy with (NC) and without (NwC) cataplexy.
RESULTS: A total of 26 patients (pts), 6 in the survey and 20 in the literature were found. Two different types of association were identified: (1) Symptomatic type (5 pts): MS preceding the onset of narcolepsy, which was always without cataplexy (NwC); sleep onset REM episodes (SOREM) and hypocretin deficiency were observed in some, and lesions in the hypothalamus in all patients. (2) Coexisting type (18 pts): MS preceding or following the appearance of NC with SOREM, hypocretin deficiency but no lesions in the hypothalamus. A positive effect of steroids, immunoglobulins or natalizumab on narcolepsy symptoms was observed in four patients. DISCUSSION: Narcolepsy and MS are rarely associated. In addition to NwC secondary to hypothalamic demyelination, some patients present a coexistence of MS with NC without detectable hypothalamic lesions. The rarity of reports on this association probably reflects underrecognition. The elucidation of underlying genetic and immune mechanisms needs further studies.

Entities:  

Keywords:  Autoimmunity; Cataplexy; Hypocretin; Hypothalamus; Multiple sclerosis; Narcolepsy; Oligoclonal bands

Mesh:

Year:  2018        PMID: 29974206     DOI: 10.1007/s00415-018-8949-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy.

Authors:  Arash Zandian; Björn Forsström; Anna Häggmark-Månberg; Jochen M Schwenk; Mathias Uhlén; Peter Nilsson; Burcu Ayoglu
Journal:  J Proteome Res       Date:  2017-02-09       Impact factor: 4.466

2.  The underdiagnosis of sleep disorders in patients with multiple sclerosis.

Authors:  Steven D Brass; Chin-Shang Li; Sanford Auerbach
Journal:  J Clin Sleep Med       Date:  2014-09-15       Impact factor: 4.062

3.  NAPS-MS: Natalizumab Effects on Parameters of Sleep in Patients with Multiple Sclerosis.

Authors:  Richard A Sater; Mark Gudesblatt; Kiren Kresa-Reahl; David W Brandes; Pamela Sater
Journal:  Int J MS Care       Date:  2016 Jul-Aug

4.  Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy.

Authors:  Hyun Hor; Zoltán Kutalik; Yves Dauvilliers; Armand Valsesia; Gert J Lammers; Claire E H M Donjacour; Alex Iranzo; Joan Santamaria; Rosa Peraita Adrados; José L Vicario; Sebastiaan Overeem; Isabelle Arnulf; Ioannis Theodorou; Poul Jennum; Stine Knudsen; Claudio Bassetti; Johannes Mathis; Michel Lecendreux; Geert Mayer; Peter Geisler; Antonio Benetó; Brice Petit; Corinne Pfister; Julie Vienne Bürki; Gérard Didelot; Michel Billiard; Guadalupe Ercilla; Willem Verduijn; Frans H J Claas; Peter Vollenweider; Peter Vollenwider; Gerard Waeber; Dawn M Waterworth; Vincent Mooser; Raphaël Heinzer; Jacques S Beckmann; Sven Bergmann; Mehdi Tafti
Journal:  Nat Genet       Date:  2010-08-15       Impact factor: 38.330

5.  The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort.

Authors:  C Hublin; J Kaprio; M Partinen; M Koskenvuo; K Heikkila; S Koskimies; C Guilleminault
Journal:  Ann Neurol       Date:  1994-06       Impact factor: 10.422

6.  HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.

Authors:  Robert Zivadinov; Laura Uxa; Alessio Bratina; Antonio Bosco; Bhooma Srinivasaraghavan; Alireza Minagar; Maja Ukmar; Su yen Benedetto; Marino Zorzon
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

7.  Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy.

Authors:  Olivier Andlauer; Hyatt Moore; Seung-Chul Hong; Yves Dauvilliers; Takashi Kanbayashi; Seiji Nishino; Fang Han; Michael H Silber; Tom Rico; Mali Einen; Birgitte R Kornum; Poul Jennum; Stine Knudsen; Sona Nevsimalova; Francesca Poli; Giuseppe Plazzi; Emmanuel Mignot
Journal:  Sleep       Date:  2012-09-01       Impact factor: 5.849

8.  Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness.

Authors:  Iris-Katharina Penner; Eva Catharina Sivertsdotter; Elisabeth G Celius; Siegrid Fuchs; Karen Schreiber; Sara Berkö; Anders Svenningsson
Journal:  Front Neurol       Date:  2015-02-23       Impact factor: 4.003

9.  Monozygotic twins discordant for narcolepsy type 1 and multiple sclerosis.

Authors:  Poul J Jennum; Birgitte R Kornum; Nadia M Issa; Steen Gammeltoft; Niels Tommerup; Niels Morling; Zeynep Tümer; Stine Knudsen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-06-16

10.  Class II HLA interactions modulate genetic risk for multiple sclerosis.

Authors:  Loukas Moutsianas; Luke Jostins; Ashley H Beecham; Alexander T Dilthey; Dionysia K Xifara; Maria Ban; Tejas S Shah; Nikolaos A Patsopoulos; Lars Alfredsson; Carl A Anderson; Katherine E Attfield; Sergio E Baranzini; Jeffrey Barrett; Thomas M C Binder; David Booth; Dorothea Buck; Elisabeth G Celius; Chris Cotsapas; Sandra D'Alfonso; Calliope A Dendrou; Peter Donnelly; Bénédicte Dubois; Bertrand Fontaine; Lars Fugger; An Goris; Pierre-Antoine Gourraud; Christiane Graetz; Bernhard Hemmer; Jan Hillert; Ingrid Kockum; Stephen Leslie; Christina M Lill; Filippo Martinelli-Boneschi; Jorge R Oksenberg; Tomas Olsson; Annette Oturai; Janna Saarela; Helle Bach Søndergaard; Anne Spurkland; Bruce Taylor; Juliane Winkelmann; Frauke Zipp; Jonathan L Haines; Margaret A Pericak-Vance; Chris C A Spencer; Graeme Stewart; David A Hafler; Adrian J Ivinson; Hanne F Harbo; Stephen L Hauser; Philip L De Jager; Alastair Compston; Jacob L McCauley; Stephen Sawcer; Gil McVean
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

View more
  6 in total

Review 1.  Immunotherapy in Narcolepsy.

Authors:  Maria Pia Giannoccaro; Giombattista Sallemi; Rocco Liguori; Giuseppe Plazzi; Fabio Pizza
Journal:  Curr Treat Options Neurol       Date:  2020-01-30       Impact factor: 3.598

2.  Sleep disturbance and cognitive decline in multiple sclerosis patients with isolated optic neuritis as the first demyelinating event.

Authors:  Recai Türkoğlu; Gülçin Benbir; Selen Özyurt; Erdil Arsoy; Ece Akbayır; Selin Turan; Derya Karadeniz; Vuslat Yılmaz; Mehmet Gencer; Erdem Tüzün
Journal:  Int Ophthalmol       Date:  2019-08-20       Impact factor: 2.031

Review 3.  Reviewing the Clinical Implications of Treating Narcolepsy as an Autoimmune Disorder.

Authors:  Maria Pia Giannoccaro; Rocco Liguori; Giuseppe Plazzi; Fabio Pizza
Journal:  Nat Sci Sleep       Date:  2021-05-11

Review 4.  Narcolepsy Presentation in Diverse Populations: an Update.

Authors:  Karen Spruyt
Journal:  Curr Sleep Med Rep       Date:  2020-11-25

Review 5.  Narcolepsy: a model interaction between immune system, nervous system, and sleep-wake regulation.

Authors:  Daniela Latorre; Federica Sallusto; Claudio L A Bassetti; Ulf Kallweit
Journal:  Semin Immunopathol       Date:  2022-04-21       Impact factor: 11.759

Review 6.  Focus on the Complex Interconnection between Cancer, Narcolepsy and Other Neurodegenerative Diseases: A Possible Case of Orexin-Dependent Inverse Comorbidity.

Authors:  Maria P Mogavero; Alessandro Silvani; Lourdes M DelRosso; Michele Salemi; Raffaele Ferri
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.